By Kyle Morris

 

AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial, reinforcing the results of a prior trial.

The Anglo-Swedish pharma giant said results from the Destiny-Breast02 Phase 3 trial of Enhertu--trastuzumab deruxtecan--showed the trial met the primary endpoint, demonstrating a significant and clinically meaningful improvement in progression-free survival in patients.

Enhertu is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Ltd.

 

Write to Kyle Morris at kyle.morris@dowjones.com

 

(END) Dow Jones Newswires

August 15, 2022 02:27 ET (06:27 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Ago 2022 até Set 2022 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Set 2021 até Set 2022 Click aqui para mais gráficos Astrazeneca.